Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment (Q46811496)

25 December 2017

title

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment (English)

1 reference

25 December 2017

13

Eric E Schadt

1 reference

25 December 2017

author name string

Jason S Simon

1

1 reference

25 December 2017

Maha C Karnoub

2

1 reference

25 December 2017

David J Devlin

3

1 reference

25 December 2017

Maria G Arreaza

4

1 reference

25 December 2017

Ping Qiu

5

1 reference

25 December 2017

Stephanie A Monks

6

1 reference

25 December 2017

Michael E Severino

7

1 reference

25 December 2017

Paul Deutsch

8

1 reference

25 December 2017

Joanne Palmisano

9

1 reference

25 December 2017

Alan B Sachs

10

1 reference

25 December 2017

Marvin L Bayne

11

1 reference

25 December 2017

Andrew S Plump

12

1 reference

25 December 2017

publication date

16 November 2005

1 reference

25 December 2017

published in

Genomics

1 reference

25 December 2017

volume

86

1 reference

25 December 2017

issue

6

1 reference

25 December 2017

page(s)

648-656

1 reference

25 December 2017

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

A New Statistical Method for Haplotype Reconstruction from Population Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Haploview: analysis and visualization of LD and haplotype maps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Evidence for substantial fine-scale variation in recombination rates across the human genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Serum plant sterols and their relation to cholesterol absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Pharmacogenetic study of statin therapy and cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2005.08.007

10.1016/J.YGENO.2005.08.007

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16297596

1 reference

25 December 2017